Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

High-risk human papillomavirus messenger RNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women, Kenya.

Ting J, Mugo N, Kwatampora J, Hill C, Chitwa M, Patel S, Gakure H, Kimani J, Schoenbach VJ, Poole C, Smith JS.

Sex Transm Dis. 2013 Jul;40(7):584-9. doi: 10.1097/OLQ.0b013e31828e5a91.

PMID:
23965776
2.

Clinical evaluation of high-risk HPV detection on self-samples using the indicating FTA-elute solid-carrier cartridge.

Geraets DT, van Baars R, Alonso I, Ordi J, Torné A, Melchers WJ, Meijer CJ, Quint WG.

J Clin Virol. 2013 Jun;57(2):125-9. doi: 10.1016/j.jcv.2013.02.016.

PMID:
23518442
3.

Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.

Ibáñez R, Moreno-Crespi J, Sardà M, Autonell J, Fibla M, Gutiérrez C, Lloveras B, Alejo M, Català I, Alameda F, Casas M, Bosch FX, de Sanjosé S.

BMC Infect Dis. 2012 Jan 26;12:25. doi: 10.1186/1471-2334-12-25.

5.

Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.

Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M.

Cancer Cytopathol. 2013 Dec;121(12):675-87. doi: 10.1002/cncy.21325. Review.

6.

Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.

Luttmer R, Berkhof J, Dijkstra MG, van Kemenade FJ, Snijders PJ, Heideman DA, Meijer CJ.

J Clin Virol. 2015 Jun;67:59-66. doi: 10.1016/j.jcv.2015.04.004.

PMID:
25959161
7.

Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.

Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, Howard M, Chong S, Daya D, Chapman W, Chernesky M.

CMAJ. 2000 Sep 5;163(5):513-8.

8.

Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.

Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J.

Int J Gynecol Cancer. 2013 Mar;23(3):513-8. doi: 10.1097/IGC.0b013e318280f3bc.

PMID:
23334437
9.
10.

Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.

Derchain SF, Sarian LO, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo RC, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K.

J Med Screen. 2008;15(2):97-104. doi: 10.1258/jms.2008.007061.

PMID:
18573778
11.

Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.

Zhou F, Pulinthanathu R, Elgert P, Cangiarella J, Simsir A.

Diagn Cytopathol. 2015 May;43(5):381-7. doi: 10.1002/dc.23243.

PMID:
25546355
12.

The Role of Chlamydia trachomatis in High-Risk Human Papillomavirus Persistence Among Female Sex Workers in Nairobi, Kenya.

Vielot N, Hudgens MG, Mugo N, Chitwa M, Kimani J, Smith J.

Sex Transm Dis. 2015 Jun;42(6):305-11. doi: 10.1097/OLQ.0000000000000287.

13.

Performance of self-sampled HPV test in comparison with liquid based cytology.

Igidbashian S, Boveri S, Radice D, Casadio C, Spolti N, Sandri MT, Sideri M.

Eur J Obstet Gynecol Reprod Biol. 2014 Jun;177:72-6. doi: 10.1016/j.ejogrb.2014.03.028.

PMID:
24768230
14.

Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program.

Gök M, van Kemenade FJ, Heideman DA, Berkhof J, Rozendaal L, Spruyt JW, Beliën JA, Babovic M, Snijders PJ, Meijer CJ.

Int J Cancer. 2012 Mar 1;130(5):1128-35. doi: 10.1002/ijc.26128.

15.

DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women.

Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, Verhoef VM, Bulten J, Melchers WJ, van der Zee AG, Bekkers RL, Wisman GB.

Br J Cancer. 2014 Sep 9;111(6):1095-101. doi: 10.1038/bjc.2014.392.

16.

Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3.

Zhao C, Amin M, Weng B, Chen X, Kanbour-Shakir A, Austin RM.

Arch Pathol Lab Med. 2013 Jul;137(7):942-7. doi: 10.5858/arpa.2012-0307-OA.

PMID:
23050808
17.

Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.

Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, Pan QJ, Ma JF, Niyazi M, Li CQ, Li SM, Smith JS, Belinson JL, Qiao YL, Castle PE.

J Natl Cancer Inst. 2012 Feb 8;104(3):178-88. doi: 10.1093/jnci/djr532.

18.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
19.

High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, Karlsen F, Morland E, Snijders PJ, Meijer CJ.

J Clin Microbiol. 2012 Jul;50(7):2390-6. doi: 10.1128/JCM.06587-11.

Items per page

Supplemental Content

Support Center